Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Auxly Cannabis Group Inc T.XLY

Alternate Symbol(s):  CBWTF

Auxly Cannabis Group Inc. is a Canada-based consumer packaged goods company in the cannabis products market. The Company is focused on developing, manufacturing and distributing branded cannabis products. Its brands include Parcel, Back Forty, Foray, Dosecann and Kolab Project. It provides various products, including vaporizers, edibles, dried flowers, pre-rolls, capsules and oils and concentrates. The Company also conducts wholesale bulk sales of dried cannabis to various licensed producers in Canada. Its subsidiaries include Auxly Charlottetown Inc., Auxly Ottawa Inc., and Auxly Leamington Inc. The Company’s primary Cannabis 2.0 Product development, manufacturing and R&D activities are conducted by its subsidiary Auxly Charlottetown Inc. at a cannabis processing facility located in Charlottetown, Prince Edward Island. Auxly Ottawa Inc. holds licenses for cultivation and processing and conducts the Company’s primary dried flower and pre-roll manufacturing.


TSX:XLY - Post by User

Post by settoretireon Apr 09, 2023 10:53am
305 Views
Post# 35385771

Last paragraph

Last paragraph

pretty much sums it up......

Apr 01

Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.059 loss in FY 2021)

Full year 2022 results:

  • CA$0.15 loss per share (further deteriorated from CA$0.059 loss in FY 2021).
  • Revenue: CA$94.5m (up 13% from FY 2021).
  • Net loss: CA$130.3m (loss widened 184% from FY 2021).

Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada.

Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.

 

<< Previous
Bullboard Posts
Next >>